Format

Send to

Choose Destination
Vaccine. 2013 Dec 9;31(51):6079-86. doi: 10.1016/j.vaccine.2013.09.072. Epub 2013 Oct 24.

Immunogenicity of a recombinant measles HIV-1 subtype C vaccine.

Author information

1
Division of Biotherapeutics, NIBSC, Potters Bar, Hertfordshire EN6 3QG, United Kingdom. Electronic address: Richard.Stebbings@nibsc.org.

Abstract

The HIV epidemic is greatest in Sub-Saharan Africa and India where HIV-1 subtype C is predominant. To control the spread of HIV in these parts of the world a preventive HIV-1 subtype C vaccine is urgently required. Here we report the immunogenicity of a candidate HIV-1 subtype C vaccine delivered by a recombinant measles vector carrying an insert encoding HIV-1 subtype C Gag, RT and Nef (MV1-F4), in MHC-typed non-human primates. HIV-1 specific cytokine secreting CD4+ and CD8+ T cell responses were detected in 15 out of 16 vaccinees. These HIV-specific T cell responses persisted in lymphoid tissues. Anti-HIV-1 antibody responses were detected in 15 out of 16 vaccinees and titres were boosted by a second immunisation carried out 84 days later. These findings support further exploration of the MV1-F4 vector as a candidate HIV-1 subtype C vaccine or as part of a wider vaccine strategy.

KEYWORDS:

HIV-1 subtype C; Humoral responses; Measles; T cell responses; Vaccine; Vector

PMID:
24161574
DOI:
10.1016/j.vaccine.2013.09.072
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center